Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 12,900 shares, an increase of 148.1% from the June 15th total of 5,200 shares. Based on an average daily volume of 52,500 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Maxim Group lowered their price target on Quoin Pharmaceuticals from $15.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, March 15th.

Institutional Investors Weigh In On Quoin Pharmaceuticals

A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.77% of Quoin Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Trading Up 0.9 %

NASDAQ:QNRX traded up $0.01 during mid-day trading on Friday, reaching $0.66. The company’s stock had a trading volume of 28,483 shares, compared to its average volume of 313,174. Quoin Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $12.00. The firm’s fifty day moving average price is $0.69 and its two-hundred day moving average price is $1.79. The stock has a market cap of $2.61 million, a P/E ratio of -0.09 and a beta of 1.97.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its earnings results on Thursday, May 9th. The company reported ($1.11) earnings per share for the quarter. Analysts predict that Quoin Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.